Phase III
4
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
8 treatments under study, led by Xkh004
Research Leaders
5 sponsors active, led by Zhejiang Kanova Biopharmaceutical Co., LTD
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
25.0%
1 terminated out of 4 trials
66.7%
-19.9% vs benchmark
100%
4 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
Trial in Low Grade Glioma Patients: Wait or Treat
Research Network
Common Treatments
- Xkh0041
- Edaravone Dexborneol Placebo1
- Radiotherapy1
- Total Coumarin Tc Cream1
- Temozolomide1
Active Sponsors
- Zhejiang Kanova Biopharmaceutical Co., LTD1
- Beijing Tiantan Hospital1
- Psoriasis Research Institute of Guangzhou1
- European Organisation for Research and Treatment of Cancer - EORTC1
- Cooperative Trials Group for Neuro-Oncology (COGNO)1
Top Investigators
EORTC Study Coordinator
Shanghai Changzheng Hospital
Beijing Tiantan Hospital
Psoriasis Research Institute of Guangzhou
Department of Dermatology, SUNY Downstate Health Sciences University
Related Conditions
- Temozolomide1
- Wait Or Treat1
- Topical Administration1
- Edaravone Dexborneol1
- Mechanical Thrombectomy1